MD Anderson Builds 13-Gene TNBC Chemotherapy Predictor From 427,857 Cells
Updated
Updated · Inside Precision Medicine · May 13
MD Anderson Builds 13-Gene TNBC Chemotherapy Predictor From 427,857 Cells
2 articles · Updated · Inside Precision Medicine · May 13
A 13-gene panel and machine-learning model built from pretreatment TNBC biopsies predicted neoadjuvant chemotherapy response before treatment and also tracked overall survival across multiple public cohorts.
The Nature study analyzed 427,857 cells from 101 early-stage patients plus spatial transcriptomics from 44 tumors, linking response to specific tumor gene programs and macrophage-rich cellular neighborhoods.
Seven of eight macrophage states—not 14 T-cell and natural-killer states—showed significant ties to response: Mac-IFN and Mac-lip-C1Q were enriched in complete responders, while Mac-angio and Mac-ECM were linked to residual disease.
TNBC makes up 10% to 20% of breast cancers, and standard neoadjuvant chemotherapy yields complete response in only 40% to 50% of early-stage cases, underscoring the need to identify likely nonresponders sooner.
Researchers said the findings could steer patients toward more individualized treatment and new macrophage-targeted strategies, though prospective validation is still needed and single-cell RNA sequencing remains costly and technically difficult.
This study splits one breast cancer into four subtypes. Are doctors actually fighting four different diseases?
A new gene test predicts chemo success in breast cancer. When will it move from the lab to the clinic?
With macrophages now key to chemo response, is today's T-cell-focused immunotherapy missing its primary target?
In May 2026, a landmark study from MD Anderson Cancer Center published in Nature used advanced single-cell RNA sequencing and spatial transcriptomics to analyze over 427,000 cells from 101 triple-negative breast cancer (TNBC) patients. This comprehensive approach provided a detailed view of the tumor microenvironment, revealing complex interactions between cancer and immune cells. The research identified distinct cellular patterns that influence disease progression and response to therapy, offering new hope for more effective and personalized TNBC care. These insights mark a significant step forward in understanding and managing this aggressive cancer type.